|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||6.19 - 6.53|
|52-week range||6.19 - 6.53|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The mean of analysts' price targets for Valneva SE Sponsored ADR (VALN) points to a 65.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Valneva SE Sponsored ADR (VALN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.